Safe(r) by design guidelines for the nanotechnology industry.

Life cycle assessment Nano-enabled products Nanoform Nanoparticles Nanoscience Risk assessment Safer by design

Journal

NanoImpact
ISSN: 2452-0748
Titre abrégé: NanoImpact
Pays: Netherlands
ID NLM: 101676795

Informations de publication

Date de publication:
01 2022
Historique:
received: 04 10 2021
revised: 24 01 2022
accepted: 24 01 2022
entrez: 13 5 2022
pubmed: 14 5 2022
medline: 18 5 2022
Statut: ppublish

Résumé

Expectations for safer and sustainable chemicals and products are growing to comply with the United Nations and European strategies for sustainability. The application of Safe(r) by Design (SbD) in nanotechnology implies an iterative process where functionality, human health and safety, environmental and economic impact and cost are assessed and balanced as early as possible in the innovation process and updated at each step. The EU H2020 NanoReg2 project was the first European project to implement SbD in six companies handling and/or manufacturing nanomaterials (NMs) and nano-enabled products (NEP). The results from this experience have been used to develop these guidelines on the practical application of SbD. The SbD approach foresees the identification, estimation, and reduction of human and environmental risks as early as possible in the development of a NM or NEP, and it is based on three pillars: (i) safer NMs and NEP; (ii) safer use and end of life and (iii) safer industrial production. The presented guidelines include a set of information and tools that will help deciding at each step of the innovation process whether to continue, apply SbD measures or carry out further tests to reduce uncertainty. It does not intend to be a prescriptive protocol where all suggested steps have to be followed to achieve a SbD NM/NEP or process. Rather, the guidelines are designed to identify risks at an early state and information to be considered to identify those risks. Each company adapts the approach to its specific needs and circumstances as company decisions influence the way forward.

Identifiants

pubmed: 35559891
pii: S2452-0748(22)00007-6
doi: 10.1016/j.impact.2022.100385
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

100385

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Auteurs

Araceli Sánchez Jiménez (A)

Institute of Occupational Medicine (IOM), Research Avenue North, Edinburgh, UK. Electronic address: araceli.sanchez@insst.mites.gob.es.

Raquel Puelles (R)

Avanzare Innovación Tecnológica S.L., Av. Lentiscares, 4-6, 26370 Navarrete, La Rioja, Spain.

Marta Perez-Fernandez (M)

Avanzare Innovación Tecnológica S.L., Av. Lentiscares, 4-6, 26370 Navarrete, La Rioja, Spain.

Leire Barruetabeña (L)

GAIKER Technology Centre, Basque Research and Technology Alliance (BRTA), Parque Tecnológico de Bizkaia, E-48170 Zamudio, Spain.

Nicklas Raun Jacobsen (NR)

National Research Centre for the Working Environment (NRCWE), Lersoe Park Alle 105, 2100 Copenhagen, Denmark.

Blanca Suarez-Merino (B)

TEMAS AG, 8048 Zurich, Switzerland.

Christian Micheletti (C)

TEMAS AG, 8048 Zurich, Switzerland.

Nicolas Manier (N)

Institut national de l'environnement industriel et des risques (INERIS), Verneuil-en-Halatte 60550, France.

Beatrice Salieri (B)

TEMAS AG, 8048 Zurich, Switzerland; Swiss Federal Laboratories for Materials Science and Technology (Empa), Technology and Society Lab (TSL), Lerchenfeldstrasse 5, 9014 St. Gallen, Switzerland.

Roland Hischier (R)

Swiss Federal Laboratories for Materials Science and Technology (Empa), Technology and Society Lab (TSL), Lerchenfeldstrasse 5, 9014 St. Gallen, Switzerland.

Rositsa Tsekovska (R)

Roumen Tsanev Institute of Molecular Biology, Bulgarian Academy of Sciences, Acad. G. Bonchev Str., bl. 21, 1113 Sofia, Bulgaria.

Yordan Handzhiyski (Y)

Roumen Tsanev Institute of Molecular Biology, Bulgarian Academy of Sciences, Acad. G. Bonchev Str., bl. 21, 1113 Sofia, Bulgaria.

Jacques Bouillard (J)

Institut national de l'environnement industriel et des risques (INERIS), Verneuil-en-Halatte 60550, France.

Yohan Oudart (Y)

Nanomakers, 1 Rue de Clairefontaine, 78 120 Rambouillet, France.

Karen S Galea (KS)

Institute of Occupational Medicine (IOM), Research Avenue North, Edinburgh, UK.

Sean Kelly (S)

Nanotechnology Industries Association (NIA), Avenue Tervueren 143, 1150 Brussels, Belgium.

Neeraj Shandilya (N)

TNO, Princetonlaan 6, 3584 CB Utrecht, Netherlands.

Henk Goede (H)

TNO, Princetonlaan 6, 3584 CB Utrecht, Netherlands.

Julio Gomez-Cordon (J)

Avanzare Innovación Tecnológica S.L., Av. Lentiscares, 4-6, 26370 Navarrete, La Rioja, Spain.

Keld Alstrup Jensen (KA)

National Research Centre for the Working Environment (NRCWE), Lersoe Park Alle 105, 2100 Copenhagen, Denmark.

Martie van Tongeren (M)

School of Health Sciences, The University of Manchester, Oxford Rd., Manchester M13 9PL,UK.

Margarita D Apostolova (MD)

Roumen Tsanev Institute of Molecular Biology, Bulgarian Academy of Sciences, Acad. G. Bonchev Str., bl. 21, 1113 Sofia, Bulgaria.

Isabel Rodríguez Llopis (IR)

GAIKER Technology Centre, Basque Research and Technology Alliance (BRTA), Parque Tecnológico de Bizkaia, E-48170 Zamudio, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH